Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IT | Common Stock | Options Exercise | $467K | +5.84K | +69.51% | $80.06 | 14.2K | May 7, 2021 | Direct | F1 |
transaction | IT | Common Stock | Disposed to Issuer | -$468K | -2K | -14.04% | $234.00 | 12.2K | May 7, 2021 | Direct | F2 |
transaction | IT | Common Stock | Tax liability | -$478K | -2.04K | -16.7% | $234.00 | 10.2K | May 7, 2021 | Direct | F3 |
transaction | IT | Common Stock | Options Exercise | $869K | +8.77K | +86.01% | $99.07 | 19K | May 7, 2021 | Direct | F1 |
transaction | IT | Common Stock | Disposed to Issuer | -$869K | -3.71K | -19.58% | $234.00 | 15.2K | May 7, 2021 | Direct | F2 |
transaction | IT | Common Stock | Tax liability | -$629K | -2.69K | -17.64% | $234.00 | 12.6K | May 7, 2021 | Direct | F3 |
transaction | IT | Common Stock | Sale | -$974K | -4.16K | -33.13% | $234.00 | 8.4K | May 10, 2021 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IT | Stock Appreciation Rights | Options Exercise | $0 | -5.84K | -100% | $0.00* | 0 | May 7, 2021 | Common Stock | 5.84K | $80.06 | Direct | F4 |
transaction | IT | Stock Appreciation Rights | Options Exercise | $0 | -8.77K | -50% | $0.00 | 8.77K | May 7, 2021 | Common Stock | 8.77K | $99.07 | Direct | F5 |
Id | Content |
---|---|
F1 | Represents shares acquired upon exercise of SARs. |
F2 | Represents shares withheld that had an aggregate value, based on the market price on the date of exercise, substantially equal to the aggregate exercise price of the SARs. |
F3 | Represents shares withheld for the payment of applicable income and payroll withholding taxes. |
F4 | These SARs were part of an award that became exercisable in four substantially equal annual installments, commencing on February 8, 2017 and are fully exercisable. |
F5 | These SARs were part of an award that became exercisable in four substantially equal annual installments, commencing on February 6, 2018 and are fully exercisable. |